Cardiac Safety Services Market
                     Cardiac Safety Services 
Market
Global Forecast to 2027
Cardiac Safety Services Market 
is expected to reach 
$ 1.0 Billion by 2027
Growing at a 
CAGR of  11.2% (2022 – 2027)
The cardiac safety services market is projected to reach USD 1.0 
billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 11.2% 
during the forecast period.
The standalone segment accounted for the second largest share of the 
type segment in the cardiac safety services market in 2021.
Standalone services are single or specific cardiac safety services offered by 
cardiac safety service providers. Some end users choose specific services 
to be performed at different phases of clinical trials per their needs. During 
preclinical and clinical trials and drug discovery, standalone services are 
mainly used by CROs and pharmaceutical and biopharmaceutical 
companies. These services are preferred due to their cost-efficiency.
The pharmaceutical & biopharmaceutical accounted for the largest 
share of the end user segment in the cardiac safety services market 
in 2021.
Pharmaceutical & biopharmaceutical companies primarily use cardiac 
safety services to manage clinical trials for newly developed drugs. 
Companies are engaged in the development of novel drugs for the 
treatment of various diseases. Cardiac safety issues are among the most 
common reasons promising drugs can be halted during development. As 
a result, there is a high demand for cardiac safety services among 
pharmaceutical and biopharmaceutical companies.
Key Market Player
lario (US), Banook Group (France), IQVIA (US), Biotrial (France), 
Certara (US), Celerion (US), Medpace (US)